Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 249 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bladder Control Clear all
Completed Phase 4 Interventional

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

NCT00333112
View directory record Official record
Conditions
Urinary Incontinence
Interventions
solifenacin succinate, tamsulosin, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 23, 2026, 8:03 PM EDT
Completed Not applicable Interventional Results available

Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial

NCT02232282
View directory record Official record
Conditions
Painful Bladder Syndrome, Interstitial Cystitis
Interventions
standard acupuncture treatment, Control Sham/Minimal Acupuncture
Device
Lead sponsor
Loyola University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 23, 2026, 8:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Chronic Pain Risk Associated With Menstrual Period Pain

NCT02214550
View directory record Official record
Conditions
Cystitis, Interstitial, Dysmenorrhea, Migraine Disorders, Pelvic Pain, Endometriosis, Visceral Pain, Chronic Pain
Interventions
cyclic microgestin 1/20, continuous microgestin 1/20
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 23, 2026, 8:03 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

NCT04241185
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only), Cisplatin, Fluorouracil (5-FU), Mitomycin C (MMC), Gemcitabine, Placebo to Pembrolizumab
Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
24
States / cities
Washington D.C., District of Columbia • Bay Pines, Florida • Orlando, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 8:03 PM EDT
Terminated Phase 2 Interventional Results available

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

NCT02591199
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
URG101, Placebo, Lidocaine, Heparin
Drug
Lead sponsor
Urigen
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Escondido, California • San Diego, California • Cartersville, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 23, 2026, 8:03 PM EDT
Recruiting Phase 4 Interventional

Gentamicin Bladder Instillation on CAUTI

NCT06332040
View directory record Official record
Conditions
Catheter Infection
Interventions
Gentamicin
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 23, 2026, 8:03 PM EDT
Recruiting Not applicable Interventional

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

NCT07234968
View directory record Official record
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy, Bladder Transitional Cell Carcinoma, Bladder Neoplasm
Interventions
Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging
Procedure · Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 23, 2026, 8:03 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

NCT01200992
View directory record Official record
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT03475706
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

NCT03980041
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Advanced Cancer
Interventions
IPI-549 (eganelisib), Nivolumab, Placebos
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Fort Wayne, Indiana • Baltimore, Maryland • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 23, 2026, 8:03 PM EDT
Completed No phase listed Observational

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

NCT06973161
View directory record Official record
Conditions
Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Other Tumors
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

NCT00739739
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
PD 0299685 at 15mg BID, PD 0299685 at 30mg BID, placebo for PD 0299685
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 23, 2026, 8:03 PM EDT
Active, not recruiting Phase 3 Interventional

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
89
States / cities
Gilbert, Arizona • Alhambra, California • Arcadia, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 8:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Controlling Urgency Through Relaxation Exercises

NCT02202031
View directory record Official record
Conditions
Overactive Bladder, Urgency Urinary Symptoms, Urgency Incontinence
Interventions
Paced Respiration, Music Therapy
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 23, 2026, 8:03 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

NCT01824303
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
LiRIS 400 mg, LiRIS Placebo
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Glendora, California • Daytona Beach, Florida • Kansas City, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Oct 23, 2026, 8:03 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

NCT01060254
View directory record Official record
Conditions
Cystitis, Interstitial, Urologic Diseases, Urinary Bladder Diseases, Cystitis
Interventions
Placebo, JNJ-42160443
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Glendora, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional

Electrical Control of Bladder in Spinal Cord Injury Patients

NCT00011570
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Bladder & Bowel Control
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 28, 2008 · Synced Oct 23, 2026, 8:03 PM EDT
Completed Not applicable Interventional

An Educational Intervention for Patients With Bladder Cancer

NCT01915121
View directory record Official record
Conditions
Bladder Cancer
Interventions
Education Intervention, Nutrition Intervention
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 23, 2026, 8:03 PM EDT
Recruiting Not applicable Interventional

Tensi+ for Treating Overactive Bladder

NCT07300904
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Tensi+
Device
Lead sponsor
Stimuli Technology
Industry
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Beverly Hills, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 8:03 PM EDT
Withdrawn Phase 3 Interventional

Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer

NCT02438852
View directory record Official record
Conditions
Bladder Carcinoma, Post-operative Pain
Interventions
Placebo, Questionnaire Administration, Ropivacaine Hydrochloride
Other · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 23, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome

NCT02411110
View directory record Official record
Conditions
Cystitis, Interstitial, Painful Bladder Syndrome
Interventions
LiRIS®, LiRIS Placebo
Combination Product
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
31
States / cities
Mobile, Alabama • Escondido, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Oct 23, 2026, 8:03 PM EDT
Terminated Not applicable Interventional Results available

TENS Used for Pain Management During Office Cystoscopy Botox Injections

NCT04448171
View directory record Official record
Conditions
Overactive Bladder
Interventions
Active TENS, Sham TENS
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 23, 2026, 8:03 PM EDT
Completed Not applicable Interventional

Pillars4Life Trial

NCT02465892
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer, Pancreatic Cancer, Liver Cancer, Renal Cancer, Bladder Cancer, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Pillars4Life
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 8:03 PM EDT
Completed Not applicable Interventional

A Longitudinal Study to Evaluate an Extracellular Matrix (MatriStem®) for the Treatment of Diabetic Foot Ulcers

NCT02750280
View directory record Official record
Conditions
Neuropathic Diabetic Foot Ulcer
Interventions
MatriStem® [Urinary Bladder Matrix (UBM)], Mepilex® [Silicone foam dressing]
Device
Lead sponsor
Calvary Hospital, Bronx, NY
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Oct 23, 2026, 8:03 PM EDT